Rizwan Haq MD, PhD is a board certified medical oncology, Assistant Physician in Medicine, Massachusetts General Hospital, and Instructor in Medicine at Harvard Medical School. He attended the University of Toronto where he obtained a bachelor's degree (BA) with numerous honors. He received both his medical degree (MD), and a Doctor of Philosophy (PhD) in molecular genetics at the University of Toronto. He completed his residency at the Osler Medical Housestaff Training Program at Johns Hopkins Hospital in Baltimore, followed by an oncology fellowship at Dana-Farber/Harvard Cancer Center.
Dr. Haq is a physician-scientist performing basic science and clinical research to improve current generation of melanoma therapies. He has published numerous articles and abstracts in oncology, including in Cancer Cell, Proceedings of the National Academy of Sciences USA and a contributing author in other papers in cancer that have been published in Nature and Molecular Cell. Also, he has authored several book chapters and is a reviewer for several journals. Some of the papers have received press coverage.
Haq R, et al (2011). Biology and clinical relevance of the micropthalmia family of transcription factors in human cancer. Journal of Clinical Oncology, 29(25):3474-82.
Haq R, et al. (2011). A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature 13;480(7375):99-103.
Haq R, et al. (2013). BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. PNAS, 110(11):4321-6.
Haq R, et al. (2013). Oncogenic BRAF regulates oxidative metabolism via PGC4? and MITF. Cancer Cell, 23(3):302-15.